Plasma Fractionation Market

Plasma Fractionation Market Overview

The global plasma fractionation market valued at $ 5.3 billion in 2025, is projected to reach $ 5.8 billion in 2026 and $ 12.7 billion by 2035, representing a higher CAGR of 9.1% during the forecast period 2026 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of company, the in-house manufacturers’ segment holds the highest share of the market.In terms of scale of operation, the commercial segment dominates the global market.
• Based on the type of plasma-derived therapeutic products manufactured, immunoglobulins segment holds the largest market share (nearly 50%) in 2025.
• With respect to therapeutic area of plasma-derived products, immunological disorders segment is anticipated to capture higher market share in 2025, and this trend is unlikely to change in future.
• In terms of geographical regions, North America captures the majority of the market share.

Market Overview

Over the past two decades, the number of patients affected with rare diseases have increased tremendously. In fact, over 410 million people are currently suffering from rare and chronic disorders. Given the growing prevalence of the aforementioned disorders, the demand for plasma derived therapies that have proven to be effective treatment option, has also observed an incremental hike. In order to cater to the rising demand for these plasma-derived therapies, an uninterrupted supply of blood plasma becomes imperative.

Currently, the US is the hub of plasma donation centers, with ~80% of the world’s plasma donation centers. In fact, the country alone supplies more than 70% of plasma to the plasma fractionator for the manufacturing of plasma-derived therapies after the process of plasma fractionation.

It is worth mentioning that plasma fractionation is a crucial process to ensure separation and purification of key blood plasma components, such as immunoglobulins, albumins, anticoagulant factors and protease inhibitors. The refined blood plasma components / fractions then can be used for formulation of therapeutics. In fact, the plasma derived therapies hold immense significance as lifesaving treatments for patients worldwide, especially those afflicted with rare and complex diseases. we believe that, as the need for these critical medicines rises, ongoing advancements in blood plasma fractionation and plasma manufacturing technology are anticipated to ensure timely access to those in need, in the foreseen future.

Plasma Fractionation Market Trends

• Opening of plasma centers in the US, driven by the impending tariffs on non-US sourced raw materials. In September 2025, GC Biopharma’s US subsidiary ABO Plasma opened a plasma center in Texas. Octapharma Plasma opened a plasma donation center in Kentwood in October 2025.
• The market is dominated by a few key companies that have undertaken several efforts to ensure the supply of plasma. For instance, Takeda acquired BioLife Plasma Services in 2019, which at the time of acquisition had more than 140 plasma collection centers across four countries. In January 2022, Grifols acquired Prometic Plasma Resources Inc's plasma donation center in Canada, the former company’s first collection center in the region.

Plasma Fractionation Market Share Insights

Immunoglobulins Segment Holds the Largest Market Share

• Currently, the global market for plasma manufacturing is dominated by plasma fractionation companies involved in fractionating immunoglobulins.
• This segment captures more than 45% of the market share and is likely to grow at a CAGR of more than 9% during the forecast period.

Market Insights

Current Plasma Fractionation Market Landscape

The plasma fractionation market features a mix of large, mid-sized and small companies, that have the required expertise to manufacture various types of plasma derived products. The market is consolidated, with the large commercial plasma fractionators acquiring the smaller regional industry players. In 2017, CSL Behring acquired Wuhan Zhong Yuan Rui De Biological Products, a China based plasma fractionator with one manufacturing facility and four plasma collection centers. Grifols also acquired a plasma fractionation facility in Canada, with 1.5 million liter annual capacity, from South Korea based GC Pharma in October 2020. There have been more such instances of mergers and acquisitions for market consolidation.

At present, more than 35 companies fractionate plasma in-house to manufacture plasma therapies. Takeda, being one such in-house plasma fractionator, announced its plans to set up a new plasma therapy manufacturing facility in Osaka, Japan in March 2023. The plant will be built with an investment of $ 754 million and will be capable of plasma fractionation and end-to-end manufacturing of plasma derived therapies.

In terms of geographical presence, we have identified more than 85 plasma facilities, through which these companies perform plasma fractionation. The majority of these facilities are located in Asia-Pacific, followed by Europe and North America. Further, nearly 20% of the plasma fractionation companies have the capability to operate at all the scales of operation from preclinical to commercial.

Market Drivers: Growing List of Plasma-derived Products

Human blood plasma contains more than 4,000 proteins, each having essential physiological functions and potential therapeutic benefits. However, ~30 such proteins are suitable for manufacturing various plasma-derived medicinal products to treat a wide range of indications.

List of plasma-derived products that received Biologics License Applications (BLAs) approval include alpha-1 proteinase inhibitor, antihemophilic factor, antithrombin, C1 esterase inhibitor, coagulation factors, fibrin, fibrinogen, immune globulins, protein C and thrombin.

In addition to the aforementioned products, several other blood plasma products have also been approved by the USFDA. Examples of these include albumins, alpha antitrypsin, antihemophilic factor (recombinant), antihemophilic factor / von willebrand factor complex, anti-inhibitor coagulant complex, antithrombin (recombinant), corifact, profilnine SD - factor IX complex, kcentra (prothrombin complex concentrate, human), protein C concentrate, thrombin and von willebrand factor (recombinant).

Technological Advancements in Fractionation Technologies to Support the Growing Demand

The plasma industry is actively exploring ways to enhance efficacy and reduce the cost of plasma-derived therapies through various measures, including adoption of new plasma fractionation technologies and increased automation.

These efforts will aid to meet the rising demand for plasma-derived therapies and ensure patients' access to essential treatments.

Market Segmentation Insights

Key Report Segments

Frequently Asked Questions